Decreased erythropoietin response in patients with the anemia of cancer

Carole B. Miller, Richard J Jones, Steven Piantadosi, Martin D. Abeloff, Jerry L Spivak

Research output: Contribution to journalArticle

Abstract

Patients with solid tumors are often anemic even before they undergo cytotoxic therapy. Since the cause of the anemia of cancer is unknown, we examined the possible role of erythropoietin. Using a sensitive radioimmunoassay, we determined serum immunoreactive erythropoietin levels in 81 anemic patients with solid tumors. For any given degree of anemia, the serum concentration of immunoreactive erythropoietin was lower in this group of patients than in a group of control patients with iron-deficiency anemia (P = 0.0001). Furthermore, the expected inverse linear relation between serum levels of immunoreactive erythropoietin and of hemoglobin was absent in the group with cancer. The erythropoietin response was further decreased in patients receiving chemotherapy; it was not influenced by the presence or absence of cisplatin in the treatment regimen. The inability of the patients with cancer to produce erythropoietin was not absolute; if they had hypoxemia, adequate erythropoietin production was restored. We conclude that erythropoietin levels are inappropriately low in anemia associated with cancer, and that erythropoietin deficiency may contribute to the development of this form of anemia. Treatment of the anemia of cancer with erythropoietin may be of value.

Original languageEnglish (US)
Pages (from-to)1689-1692
Number of pages4
JournalNew England Journal of Medicine
Volume322
Issue number24
StatePublished - Jun 14 1990

Fingerprint

Erythropoietin
Anemia
Neoplasms
Serum
Iron-Deficiency Anemias
Cisplatin
Radioimmunoassay
Hemoglobins
Therapeutics
Drug Therapy
Control Groups

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Decreased erythropoietin response in patients with the anemia of cancer. / Miller, Carole B.; Jones, Richard J; Piantadosi, Steven; Abeloff, Martin D.; Spivak, Jerry L.

In: New England Journal of Medicine, Vol. 322, No. 24, 14.06.1990, p. 1689-1692.

Research output: Contribution to journalArticle

Miller, Carole B. ; Jones, Richard J ; Piantadosi, Steven ; Abeloff, Martin D. ; Spivak, Jerry L. / Decreased erythropoietin response in patients with the anemia of cancer. In: New England Journal of Medicine. 1990 ; Vol. 322, No. 24. pp. 1689-1692.
@article{75760413f1df419f851e2ab0d73c94d9,
title = "Decreased erythropoietin response in patients with the anemia of cancer",
abstract = "Patients with solid tumors are often anemic even before they undergo cytotoxic therapy. Since the cause of the anemia of cancer is unknown, we examined the possible role of erythropoietin. Using a sensitive radioimmunoassay, we determined serum immunoreactive erythropoietin levels in 81 anemic patients with solid tumors. For any given degree of anemia, the serum concentration of immunoreactive erythropoietin was lower in this group of patients than in a group of control patients with iron-deficiency anemia (P = 0.0001). Furthermore, the expected inverse linear relation between serum levels of immunoreactive erythropoietin and of hemoglobin was absent in the group with cancer. The erythropoietin response was further decreased in patients receiving chemotherapy; it was not influenced by the presence or absence of cisplatin in the treatment regimen. The inability of the patients with cancer to produce erythropoietin was not absolute; if they had hypoxemia, adequate erythropoietin production was restored. We conclude that erythropoietin levels are inappropriately low in anemia associated with cancer, and that erythropoietin deficiency may contribute to the development of this form of anemia. Treatment of the anemia of cancer with erythropoietin may be of value.",
author = "Miller, {Carole B.} and Jones, {Richard J} and Steven Piantadosi and Abeloff, {Martin D.} and Spivak, {Jerry L}",
year = "1990",
month = "6",
day = "14",
language = "English (US)",
volume = "322",
pages = "1689--1692",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "24",

}

TY - JOUR

T1 - Decreased erythropoietin response in patients with the anemia of cancer

AU - Miller, Carole B.

AU - Jones, Richard J

AU - Piantadosi, Steven

AU - Abeloff, Martin D.

AU - Spivak, Jerry L

PY - 1990/6/14

Y1 - 1990/6/14

N2 - Patients with solid tumors are often anemic even before they undergo cytotoxic therapy. Since the cause of the anemia of cancer is unknown, we examined the possible role of erythropoietin. Using a sensitive radioimmunoassay, we determined serum immunoreactive erythropoietin levels in 81 anemic patients with solid tumors. For any given degree of anemia, the serum concentration of immunoreactive erythropoietin was lower in this group of patients than in a group of control patients with iron-deficiency anemia (P = 0.0001). Furthermore, the expected inverse linear relation between serum levels of immunoreactive erythropoietin and of hemoglobin was absent in the group with cancer. The erythropoietin response was further decreased in patients receiving chemotherapy; it was not influenced by the presence or absence of cisplatin in the treatment regimen. The inability of the patients with cancer to produce erythropoietin was not absolute; if they had hypoxemia, adequate erythropoietin production was restored. We conclude that erythropoietin levels are inappropriately low in anemia associated with cancer, and that erythropoietin deficiency may contribute to the development of this form of anemia. Treatment of the anemia of cancer with erythropoietin may be of value.

AB - Patients with solid tumors are often anemic even before they undergo cytotoxic therapy. Since the cause of the anemia of cancer is unknown, we examined the possible role of erythropoietin. Using a sensitive radioimmunoassay, we determined serum immunoreactive erythropoietin levels in 81 anemic patients with solid tumors. For any given degree of anemia, the serum concentration of immunoreactive erythropoietin was lower in this group of patients than in a group of control patients with iron-deficiency anemia (P = 0.0001). Furthermore, the expected inverse linear relation between serum levels of immunoreactive erythropoietin and of hemoglobin was absent in the group with cancer. The erythropoietin response was further decreased in patients receiving chemotherapy; it was not influenced by the presence or absence of cisplatin in the treatment regimen. The inability of the patients with cancer to produce erythropoietin was not absolute; if they had hypoxemia, adequate erythropoietin production was restored. We conclude that erythropoietin levels are inappropriately low in anemia associated with cancer, and that erythropoietin deficiency may contribute to the development of this form of anemia. Treatment of the anemia of cancer with erythropoietin may be of value.

UR - http://www.scopus.com/inward/record.url?scp=0025315364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025315364&partnerID=8YFLogxK

M3 - Article

C2 - 2342534

AN - SCOPUS:0025315364

VL - 322

SP - 1689

EP - 1692

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 24

ER -